

25 Apr 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year's drug launches.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 April 2021, including: possible new life for Tecfidera; activist investors and GSK; a new mRNA vaccine in Europe; diversity in clinical trials; and a look at last year's drug launches amid the pandemic.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen](#)" - Scrip, 19 Apr, 2021.)

(Also see "[Twitchy Times At GSK As Activist Investor Takes Big Stake](#)" - Scrip, 16 Apr, 2021.)

(Also see "[CureVac Could Be Third mRNA Vaccine Approval – But With A 'Europe First' Approach](#)" - Scrip, 16 Apr, 2021.)

(Also see "[#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity](#)" - Scrip, 16 Apr, 2021.)

(Also see "[\*Worldwide Novel Drug Launches Soared Amid Pandemic\*](#)" - Scrip, 19 Apr, 2021.)

[\*Click here to explore this interactive content online\*](#) ✨